Viral Genetics Creates Subsidiary to Develop Cancer Therapy

SAN MARINO, Calif., Aug. 7 /PRNewswire-FirstCall/ -- Biotechnology company Viral Genetics (Pink Sheets: VRAL) has formed a wholly owned subsidiary called MetaCytoLytics, Inc. This company was created to advance a technology developed by University of Colorado Professor M. Karen Newe...

The Breast Cancer Therapeutics Market in Australia

SYDNEY, Aug. 5 /PRNewswire/ -- Rising public awareness of breast cancer and available treatments have increased revenues in the breast cancer therapeutics market in Australia. As the most common cancer diagnosed in Australia's female population, the total number of breast cance...

Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference

NEW YORK, July 30 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company and a leading developer of oncology compounds directed to cancer stem cell targets, today announced that the Company's CEO, Ivan Bergstein M.D. has been invited to present at the New Fron...

MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients

DALLAS, July 23 /PRNewswire-FirstCall/ -- AC C E S S PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) , announced today that its European partner, SpePharm , is collecting data from a post approval study of MuGard in head and neck cancer patients undergoing...

Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics

GAITHERSBURG, Md., July 22 /PRNewswire/ -- Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has received an SBIR (small business innovation research) grant from National Cancer Institute (NCI), National Institute of Health (NIH), for its novel siRNA therapeutics to treat...

Biomodels Expands Efforts in Cancer Supportive Care, Pulmonary Fibrosis; Preclinical Research Organization Names Dr. Stephen T. Sonis as Partner

WATERTOWN, Mass., July 22 /PRNewswire-USNewswire/ -- Biomodels LLC, a pre-clinical research organization best known for its expertise in oral mucositis, today announced it will further increase its work in the areas of cancer supportive care, pulmonary fibrosis, and biphosphonate-r...

Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies

EXTON, Pa., July 15 /PRNewswire/ -- Morphotek((R)), Inc., a subsidiary of Eisai Corporation of North America, and Cancer Innovations, Inc. (CII), a privately held biotechnology company specializing in the development of oncology products, today announced that they have entered into an ev...

University of Florida Shands Cancer Center Selects OnCore(r) to Support its Collaborative Research Goals

An institutional goal to develop collaborative partnerships with other research organizations was a key factor in the recent decision by the University of Florida Shands Cancer Center (UFSCC) to select OnCore(r) products in support of their clinical and translational research informatics needs. W...

ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens

HALIFAX, NS, July 14 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, has entered into an agreement to exclusively license seven cancer antigens from Immunotope Inc., an antigen discovery company. These proprietary antigens specifically target breast, ovarian an...

Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial

TAMPA, Fla., July 14 /PRNewswire/ -- Quantum Immunologics, Inc. (QI), a Tampa, Florida company focusing on the research and development of cancer immunotherapies, announces that the first patient in its breast cancer trial has begun to receive its dendritic cell therapy. QI is...

First Catalog Cancer Biochip for Sequence Capture Now Available from febit

LEXINGTON, Mass. and HEIDELBERG, Germany, July 13 /PRNewswire/ -- febit holding gmbh announced today the launch of the first human cancer biochip for HybSelect, febit's highly automated technology for sequence capture, enabling targeted Next-Generation Sequencing (NGS). The new catal...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue. World Prostate Cancer Therapeutics Market http://www.reportlinker.com/p0119471/World-Prostate-Cancer-Therapeutics-Market.html?utm_source=PRNWire&utm_medium=PR&utm_c...

Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)

PITTSBURGH, July 7 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Bicalutamide Tablets, 50 mg. Bical...

Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models

EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National Institutes of Health and Lixte r...

Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial

CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel/carboplatin for patients with advanced cancers. The princ...

Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease

EXTON, Penn., July 1 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of can...

Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010

SEATTLE, June 26 /PRNewswire/ -- The Fred Hutchinson Cancer Research Center board of trustees today announced that its president and director, Lee Hartwell, Ph.D., plans to retire in June 2010. Hartwell, a recipient of the 2001 Nobel Prize in physiology or medicine, has been president and director...

2009 Medical Innovation Summit at Cleveland Clinic to Highlight the Latest Developments in Cancer Care

CLEVELAND , June 24 /PRNewswire/ -- Cancer therapies and diagnostics, including new technologies, enhanced biotech and drug developments, and the consumer market for genetic testing, will be at the center of Cleveland Clinic's 7th Annual Medical Innovation Summit, Oct. 5-7. The Summit will b...

YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB

MISSISSAUGA, ON, June 23 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI , TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that its li...

The Lustgarten Foundation Awards Six Research Centers With Pancreatic Cancer Research Funding

Foundation Expects to Double 2009 Grant Awards to Nearly $4 Million BETHPAGE, N.Y., June 23 /PRNewswire-USNewswire/ -- The Lustgarten Foundation, the nation's largest private supporter of pancreatic cancer research, today announced its first round of 2009 grants, totaling $1.6 million awar...

Exosome Diagnostics and DxS Diagnostic Innovations Collaborate to Develop Blood-Based Tests for Key Cancer Mutations

NEW YORK, June 22 /PRNewswire/ -- Exosome Diagnostics, Inc. ("ExosomeDX") and DxS Ltd. ("DxS") today announced that they will collaborate on the development of blood-based companion diagnostics for key cancer gene mutations, such as KRAS, BRAF and EGFR. The collaboration will use DxS' industry le...

Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy

TROMS0, Norway and SEOUL, Korea, June 19 /PRNewswire/ -- The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax today announced the signing of a collaborative agreement to test lead compounds LTX-315 and GV1001 as a combination therapy for the treatment of cance...

Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours

LAUSANNE, Switzerland and TAMPA, Florida, June 18 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Moffitt Cancer Center (Moffitt), a non-profit Fl...

DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research

DNA Genotek to Provide Method for Easy, Reliable and Non-Invasive DNA Collection On-Site at Komen Western New York Race for the Cure® Ottawa, ON (PRWEB) June 12, 2009 -- DNA Genotek , a leading provider of products for biological sample collection, today announced ...

Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market

VEENENDAAL, The Netherlands, June 2 /PRNewswire/ -- Nucletron BV, the innovative cancer radiation solutions company, today announced the creation of an exclusive partnership and plan to merge with sector peer Isodose Control BV for an undisclosed sum. The two companies, headquartered in Veenen...

Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting

- Interim Primary Endpoint Data from Phase II Study Shows 71% Objective Tumor Response Rate in Evaluable Patients Receiving Bavituximab Plus Docetaxel - - Secondary Endpoint Evaluation Shows Promising 7.4 Month Median Progression Free Survival in Initial Study Cohort - ORLANDO, Fla. and ...

Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients

Data Presented Today at American Society of Clinical Oncology ORLANDO, Fla., June 1 /PRNewswire/ -- Precision Therapeutics, Inc. today presented data demonstrating the use of ChemoFX(R), a chemosensitivity assay, to predict the effectiveness of cetuximab (ERBITUX(R)) on the colorectal cancer ...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

- Results from a randomized Phase IIb trial reported at 2009 ASCO Annual Meeting - MISSISSAUGA, ON, June 1 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI , TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio ...

AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting

QUEBEC CITY, June 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it presented results supporting the evaluation of its targeted cytotoxic peptide conjugate compound, AE...

OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial

BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) today announced preliminary results of a Phase 1 trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Preliminary results as of A...

Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting

MADISON, N.J., May 28 /PRNewswire-FirstCall/ -- Quest Diagnostics scientists will present results of three studies revealing the effect of genomic abnormalities on the diagnosis and treatment of chronic myeloid leukemia (CML) and prostate cancer during the 45th Annual Meeting of the American Socie...

Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting

- Oral Presentation to Highlight Data from Phase II Study Evaluating Bavituximab in Advanced Breast Cancer - - Poster Presentation to Discuss Data from Phase I Study Evaluating Bavituximab in Multiple Tumor Types - TUSTIN, Calif., May 27 /PRNewswire-FirstCall/ -- Peregrine Pharmaceutical...

Gene Network Sciences Announces Broad Cancer Collaboration With UCSF and Initial Results

CAMBRIDGE, Mass., May 27 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced that it has entered into a research collaboration with the University of California San Francisco Cancer Center (UCSF) aimed at accelerating cancer research and drug development across several therapeutic ...

Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology

A 71-year old man with inoperable lung cancer is able to receive stereotactic body radiotherapy (SBRT) treatment DOVER, N.H., May 26 /PRNewswire-FirstCall/ -- Surgeons told Donald Bickford, 71, that due to the weakened condition of his lungs, ordinary surgery was not an option for removing hi...

Prospect Therapeutics, Inc.'s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models

WELLESLEY HILLS, Mass., May 26 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that there has been promising initial interest from pharma companies in the intellectual property of Prospect Therapeutics, Inc. ("Prospect"). In preclinical studies, GCS-100 inhibited blood v...

AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting

Partner Keryx to present Phase 2 data on perifosine for multiple cancers QUEBEC CITY, May 19 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that results supporting ...

SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Germany & Austria

SAN DIEGO, May 13 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that it has established a distribution partnership for the German and Austrian markets through Krainer Medtechnik, a Vienna-based firm specializing...

Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB

STOCKHOLM, May 6 /PRNewswire/ -- Axelar AB today announced successful completion of the single-day oral dosing part of its ongoing phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717,an insulin-like growth factor-1 (IGF-1) receptor inhibitor which has no effects ...

BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management

Alliance Aims to First Develop Powerful Tools for Detecting Ovarian Cancer Earlier FRANKLIN LAKES, N.J. and MALVERN, Pa., May 4 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) and Fujirebio Diagnostics, Inc., announced today the signing of a worldwide development ...

Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign

"Coping with Cancer from the Outside In" Program to Launch at the Annual Oncology Nursing Society Congress THOUSAND OAKS, Calif., April 30 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) and ONS Edge , a subsidiary of the Oncology Nursing Society (ONS), today announced that they will part...